References
1. Saner FH, Gensicke J, Olde Damink SW, Pavlaković G, Treckmann J, Kaiser GM, et al. Neurologic complications in adult living donor liver transplant patients: an underestimated factor? J Neurol 2010;257:253–8.
2. Shawcross D, Jalan R. The pathophysiologic basis of hepatic encephalopathy: central role for ammonia and inflammation. Cell Mol Life Sci 2005;62:2295–304.
3. Schliess F, Gőrg B, Fischer R, Desjardins P, Bidmon HJ, Herrmann A, et al. Ammonia induces MK-801-sensitive nitration and phosphorylation of protein tyrosine residues in rat astrocytes. FASEB J 2002;16:739–41.
4. Lang EW, Mudaliar Y, Lagopoulos Y, Dorsch N, Yam N, Griffith J, et al. A review of cerebral autoregulation: assessment and measurements. Australasian Anaesthesia 2005. 161–72.
5. Horowitz ME, Schafer DF, Molnar P, Jones EA, Blasberg RG, Patlak CS, et al. Increased blood-brain transfer in a rabbit model of acute liver failure. Gastroenterology 1983;84:1003–11.
6. Larsen FS, Gottstein J, Blei AT. Cerebral hyperemia and nitric oxide synthase in rats with ammonia-induced brain edema. J Hepatol 2001;34:548–54.
7. Davies NA, Wright G, Ytrebø LM, Stadlbauer V, Fuskevåg OM, Zwingmann C, et al. L-ornithine and phenylacetate synergistically produce sustained reduction in ammonia and brain water in cirrhotic rats. Hepatology 2009;50:155–64.
8. Jiang Q, Jiang XH, Zheng MH, Jiang LM, Chen YP, Wang L. Rifaximin versus nonabsorbable disaccharides in the management of hepatic encephalopathy: a meta-analysis. Eur J Gastroenterol Hepatol 2008;20:1064–70.
9. Kircheis G. Current state of knowledge of hepatic encephalopathy (Part V): clinical efficacy of L-ornithine-L-aspartate in the management of HE. Metab Brain Dis 2016;31:1365–7.
10. Kircheis G, Wettstein M, Dahl SV, Häussinger D. Clinical efficacy of L-ornithine-L-aspartate in the management of hepatic encephalopathy. Metab Brain Dis 2002;17:453–62.
11. Ytrebø LM, Kristiansen RG, Maehre H, Fuskevåg OM, Kalstad T, Revhaug A, et al. L-ornithine phenylacetate attenuates increased arterial and extracellular brain ammonia and prevents intracranial hypertension in pigs with acute liver failure. Hepatology 2009;50:165–74.
12. Munñoz SJ, Robinson M, Northrup B, Bell R, Moritz M, Jarrell B, et al. Elevated intracranial pressure and computed tomography of the brain in fulminant hepatocellular failure. Hepatology 1991;13:209–12.
13. Kumar R, Shalimar , Sharma H, Goyal R, Kumar A, Khanal S, et al. Prospective derivation and validation of early dynamic model for predicting outcome in patients with acute liver failure. Gut 2012;61:1068–75.
14. Bhatia V, Batra Y, Acharya SK. Prophylactic phenytoin does not improve cerebral edema or survival in acute liver failure--a controlled clinical trial. J Hepatol 2004;41:89–96.
15. Rajajee V, Fontana RJ, Courey AJ, Patil PG. Protocol based invasive intracranial pressure monitoring in acute liver failure: Feasibility, safety and impact on management. Crit Care 2017;21178,017-. :1762–6.
16. Jalan R, Olde Damink SW, Deutz NE, Hayes PC, Lee A. Moderate hypothermia in patients with acute liver failure and uncontrolled intracranial hypertension. Gastroenterology 2004;127:1338–46.
17. Stravitz RT, Larsen FS. Therapeutic hypothermia for acute liver failure. Crit Care Med 2009;37:S258–64.